Conference Coverage

This channel highlights DAIC's coverage of numerous key cardiology and medical imaging conferences each year. These include ACC, AHA, ASE, ASNC, EuroPCR, ECR, HIMSS, HRS, RSNA, SCAI, SCCT, TCT, and VIVA.

Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions.

Feature | EP Lab | By Dave Fornell, Editor

Etripamil Nasal Spray Reduced ER Vistsis and More PSVT Resolution in New NODE-301 Analysis

May 16, 2020 — New data from in the NODE-301 Trial for the patient-administered nasal spray etripamil to resolve ...

May 16, 2021

The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman

Feature | Left Atrial Appendage (LAA) Occluders

NCDR LAAO Registry Shows Left Atrial Appendage Occlusion Associated With Low Rate of Stroke

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

May 16, 2021

The mechanism of action for mavacamten, a cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (oHCM). EXPLORER-HCM trial #ACC21 #ACC2021

News | Pharmaceuticals

Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy

May 15, 2021 — A new analysis of the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in ...

May 15, 2021

The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor. #ACC21 #ACC2021

News | Heart Failure

Sacubitril/Valsartan Does Not Outperform ACE Inhibitor in Preventing Heart Failure After Heart Attack

May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the rate ...

May 15, 2021

In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. #ACC21 #ACC2021

News | Left Atrial Appendage (LAA) Occluders

Left Atrial Appendage Occlusion Reduces Stroke After Heart Surgery

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

May 15, 2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

News | Antiplatelet and Anticoagulation Therapies

Baby and Regular Strength Aspirin Equal in Cardiac Platelet Inhibition and Safety

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

May 15, 2021

An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eloquis is not a good solution.

News | Structural Heart

TAVR Anticoagulation With Apixaban Not Superior to Standard Care

May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic ...

May 15, 2021

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

Feature | Cath Lab | By Dave Fornell, Editor

Creating a Cardio-renal Program to Expand Patient Volume

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

May 14, 2021

Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire.

Feature | Structural Heart | By Dave Fornell, Editor

The Emory Angle Can Help Eliminate Paravalvular Leak in Transcatheter Mitral Interventions

The mitral valve anatomy is extremely complex, which has caused many challenges for transcatheter mitral valve ...

May 13, 2021

Videos | Structural Heart

VIDEO: Harmony Transcatheter Pulmonary Valve Has Good Outcomes at 1 Year

Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, and principle investigator ...

May 13, 2021

The Consumer Technology Association (CTA) is collaborating with the American College of Cardiology (ACC) and several vendors on best practices for device and app and wearable device makers to provide deeper understanding of products that manage cardiovascular health. #wearables

News | Wearables

Vendors and ACC Collaborate With Consumer Technology Association to Help Clinicians and Patients Understand Cardiovascular Devices

May 10, 2021 – Today, the Consumer Technology Association (CTA) announced it is collaborating with the American College ...

May 10, 2021

Videos | Radial Access

VIDEO: Radial Hemostasis Reduced by 50 Percent With StatSeal in Combination With TR Band

Arnold Seto, M.D., MPA, FSCAI, chief of cardiology, Long Beach Veterans Affairs Medical Center and director ...

May 06, 2021

Videos | Coronavirus (COVID-19)

VIDEO: The Impact of COVID-19 on Heart Attack Patients

Payam Dehghani, M.D., FRCPC, FACC, FSCAI, co-director of Prairie Vascular Research and associate professor at the ...

May 06, 2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

Feature | Cath Lab | By Dave Fornell, Editor

SCAI 2021 Late-breaking Clinical Study Results

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

May 06, 2021

Videos | Cath Lab

VIDEO: Avoiding Higher Risk Cath Lab Patients May Not Improve Outcomes Scores

Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of ...

May 05, 2021